Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular telangiectasia type 2

Matt, G.; Sacu, Stefan; Ahlers, C.; Schütze, Christopher; Dunavoelgyi, Roman; Prager, Franz; Pruente, Christian; Schmidt‐Erfurth, Ursula

doi:10.1038/eye.2010.113

Cited by 18 publications

(10 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15,17,20,22 Similarly, though decreases in macular thickness measured by OCT may be detected initially, 12,16,17,18,19,20,21,22,24 studies with long-term follow-up after the final injection reported that OCT findings also returned to baseline. 17,18,20,22 Besides these studies, there are others in which no substantial changes in OCT findings were observed. 13,14,15 Results concerning visual acuity vary.…”

Section: Discussionmentioning

confidence: 97%

“…12,15,16,17,18,19,20,21,22 In some of these studies, however, the leakage on FA was reported to return to baseline levels during periods without injections. 15,17,20,22 Similarly, though decreases in macular thickness measured by OCT may be detected initially, 12,16,17,18,19,20,21,22,24 studies with long-term follow-up after the final injection reported that OCT findings also returned to baseline. 17,18,20,22 Besides these studies, there are others in which no substantial changes in OCT findings were observed.…”

Section: Discussionmentioning

confidence: 98%

“…In recent years, intravitreal anti-vascular endothelial growth factor (VEGF) injection has been administered to proliferative and nonproliferative patient groups in a variety of studies. 12,13,14,15,16,17,18,19,20,21,22,23,24 Although the results of these studies differ, some patients reportedly benefited from intravitreal anti-VEGF injections.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia

Aydoğan

Erdoğan

Ünlü

et al. 2016

tjo

View full text Add to dashboard Cite

Objectives: To evaluate the efficacy of intravitreal bevacizumab treatment in type 2 idiopathic macular telangiectasia (IMT).Materials and Methods: Six eyes of 5 patients with type 2 IMT who received intravitreal bevacizumab between 2009 and 2014 were included in this study. All the patients had an ophthalmological examination including best corrected visual acuity (BCVA), dilated fundus examination, spectral domain optical coherence tomography (OCT) and fluorescein angiography. Intravitreal bevacizumab injection was planned for patients who had macular edema and/or decreased visual acuity at baseline. Patients were examined 1 week and 1 month after the intravitreal injection. Intravitreal injection was repeated in patients whose visual acuity decreased and/or whose macular edema persisted or increased. Changes in BCVA, central macular thickness (CMT) and central macular volume from baseline at 1 month after the first injection and at final examination were evaluated.Results: Average age of the patients (4 female and 1 male) was 62±11.8 years. Average follow-up period was 26±11 months. Patients received an average of 2.3 (range 1-4) injections during follow-up. Average Snellen BCVA of the patients was 0.48±0.29. BCVA increased at final examination compared to baseline in all of the patients. The difference between baseline and final visual acuities was significant (p<0.05). The patients’ average CMT was 328±139 µm at baseline and decreased by a mean of 85±153 µm at 1 month after the first injection and 65±142 µm at final examination, but the changes were not significant. CMT decreased at final examination compared to baseline in four patients and increased in both eyes of one patient.Conclusion: Intravitreal bevacizumab injection is a preferable treatment method in regard to both visual acuity and OCT findings.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia

Aydoğan

Erdoğan

Ünlü

et al. 2016

tjo

View full text Add to dashboard Cite

show abstract

“…Recently, it has been hypothesized that VEGF may play an essential role in IMT, which has stimulated the use of bevacizumab or ranibizumab for the treatment of this condition (table 2) [2,3,4,5,6,7,8,9,10,11,12]. Even though some authors have shown a significant visual effect [3,4,5,9,10], others have reported no significant functional improvement after intravitreal anti-VEGF treatment despite apparent anatomical changes in the decreased late-phase FA leakage and decreased CRT on OCT [6,7]. Some authors also found that intravitreal anti-VEGF agents did not reduce CMT or improve BCVA [2,8,11,12], with results similar to ours.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, type 2 IMT has been treated with anti-vascular endothelial growth factor (VEGF) agents with different results [2,3,4,5,6,7,8,9,10,11,12]. The purpose of this study is to describe a case series of patients treated with intravitreal bevacizumab (IVB) for type 2 IMT.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal Bevacizumab for Type 2 Idiopathic Macular Telangiectasia

Veloso

Vianna²,

Pelayes³

et al. 2013

Ophthalmic Res

View full text Add to dashboard Cite

Background/Aims: The aim of this paper is to report the treatment of type 2 nonproliferative idiopathic macular telangiectasia (IMT) with intravitreal bevacizumab (IVB). Methods: Retrospective case series of 10 eyes of 5 patients with type 2 IMT. All patients received 3 monthly IVB injections. Visual acuity (VA), fluorescein angiography (FA) and optical coherence tomography (OCT) were performed at baseline and 4 weeks after each injection. Results: Four weeks after the third IVB injection, VA remained stable for all patients. All eyes showed some decrease in fluorescein leakage, and there was a mild decrease in central macular thickness. One year later, VA, OCT and FA findings returned to the baseline levels. Conclusion: IVB did not improve VA in cases of type 2 IMT.

show abstract

VEGF-Inhibition in Macular Telangiectasia Type 2

Issa

Holz

2016

Anti-Angiogenic Therapy in Ophthalmology

View full text Add to dashboard Cite

Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular telangiectasia type 2

Cited by 18 publications

References 13 publications

Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia

Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia

Intravitreal Bevacizumab for Type 2 Idiopathic Macular Telangiectasia

VEGF-Inhibition in Macular Telangiectasia Type 2

Contact Info

Product

Resources

About